News Hub | News Direct

TEAM 1144's New Initiative lead by Nesty Delgado: Launch of the Project Management & Transformational Leadership Institute

UpVenturemedia

PR Content Nesty Delgado // CONTENT BRIEF TEAM 1144's New Initiative lead by Nesty Delgado: Launch of the Project Management & Transformational Leadership Institute In a landmark partnership, TEAM 1144, led by project management international speaker, educator, and consultant Nesty Delgado, and the University of Puerto Rico-Mayagüez (UPR-Mayagüez) have joined forces to launch the Project Management & Transformational Leadership Institute (PMTL Institute). This collaboration represents a significant advancement in Puerto Rico’s educational landscape, specifically in project management and transformational leadership, two fields critical to the island’s future. UPR-Mayagüez, celebrated for its outstanding School of Engineering, is the ideal partner for this initiative. The university’s reputation as the top academic institution in Puerto Rico and its commitment to excellence made it the perfect collaborator for TEAM 1144’s vision. Nesty Delgado, a proud alumnus of UPR-Mayagüez and founder of TEAM 1144, personally signed the agreement with the university’s Rector, Dr. Agustín Rullán Toro, and Dr. Roberto Seijo, Dean of the College of Business Administration. This moment marked not just a professional achievement, but a deeply personal one for Nesty Delgado, who has long held his alma mater in high regard. “The PMTL Institute aims to provide top-tier education and professional development opportunities in project management, transformational leadership, and change management. The institute’s programs are meticulously designed to equip professionals with the skills and knowledge necessary to lead complex projects, particularly those related to Puerto Rico’s ongoing reconstruction and resilience efforts. The initiative is not just about education; it’s about empowering a new generation of leaders who will drive Puerto Rico’s future forward.” Said Alba Norys De Leon, president of AblaTek, an important strategic ally in this endeavor. The Importance for Puerto Rico Puerto Rico is at a critical juncture in its history. With billions of dollars in public and private investment flowing into the island for infrastructure projects, there is a pressing need for skilled professionals who can lead these initiatives effectively. The PMTL Institute is positioned to play a pivotal role in addressing this need. Under Nesty Delgado’s guidance and TEAM 1144 experiences in several projects around the Island, the institute will offer a comprehensive curriculum that blends leadership skills and theoretical knowledge with practical application, ensuring that graduates are fully prepared to take on leadership roles in the island’s transformation. The signing of the agreement also received significant support from government leadership, with the Secretary of the Department of Economic Development and Commerce, Mr. Manuel Cidre, playing a key role in endorsing the initiative. His participation underscores the importance of this collaboration for Puerto Rico's economic future, aligning with the government’s broader efforts to drive the island’s recovery and growth through strategic investments in education and professional development. The support from such high levels of government reflects the far-reaching impact this initiative is expected to have. TEAM 1144 and UPR-Mayagüez: A Partnership for Progress This collaboration between TEAM 1144 and UPR-Mayagüez is a testament to what can be achieved when the private sector and academia come together with a shared vision. The institute’s programs are tailored to the unique challenges and opportunities facing Puerto Rico, ensuring that the skills developed are directly applicable to the local context. The inclusion of advanced topics such as change management and transformational leadership reflects the institute’s commitment to providing a holistic education that prepares professionals to not only manage projects but to lead transformational change within their organizations and communities. Dr. Roberto Seijo, the Dean of the College of Business Administration at UPR-Mayagüez, has been instrumental in bringing this vision to life. His leadership within EDUCON, the university’s continuous education unit, has ensured that the PMTL Institute’s offerings are aligned with the highest academic standards while remaining accessible to professionals across the island. This combined effort has created a powerful platform for professional growth and development in Puerto Rico. Be a Part of the Change Now is the time to make a difference. The Project Management & Transformational Leadership Institute is your gateway to becoming a leader in Puerto Rico’s ongoing transformation. Whether you are an aspiring project manager, a seasoned professional looking to enhance your skills, or someone passionate about driving positive change, this institute offers the tools and knowledge you need to succeed. Join us at the PMTL Institute and become part of the movement that is shaping the future of Puerto Rico. Enroll today, and take the first step towards a brighter, more resilient tomorrow. About TEAM 1144 TEAM 1144, led by Nesty Delgado, is a leading project management firm dedicated to innovative solutions and strategic development in Puerto Rico. The company has successfully managed high-impact projects, contributing to the island's progress and resilience. Media Contact TEAM 1144 Email: pmtlinstitute@team1144.cominfo@team1144.com Phone: (787) 123-4567 Website: https://team1144.com/ Audience Engagement We aim to engage professionals, students, and stakeholders interested in project management and transformational leadership. Our goal is to inspire participation and highlight the positive impact of this initiative. Measure Results We will measure the success of this PR through media coverage, social media engagement, website traffic, and inquiries about the Institute. Media Relations Our media relations strategy includes distributing this release to major news outlets, industry publications, and relevant blogs to maximize coverage and visibility. Brand Awareness This PR is part of our broader strategy to boost Nesty Delgado’s brand awareness and highlight TEAM 1144's contributions to Puerto Rico. Business Growth By showcasing our commitment to education and leadership development, we aim to attract new clients, partners, and opportunities for business growth. Crisis Communications & Management We are prepared to address any issues that may arise and ensure clear, transparent communication to maintain trust and credibility. Executive Thought Leadership Nesty Delgado will continue to provide thought leadership through articles, speaking engagements, and participation in industry events. Contact & Follow-Up For more information or to schedule an interview with Nesty Delgado, please contact info@team1144.com. Contact Details Nesty Delgado info@team1144.com

September 12, 2024 09:00 AM Eastern Daylight Time

Image

This EV-Based Small Cap Has Partnerships With Walmart, NASA And The U.S. Postal Service – Is It On Your Radar?

Benzinga

By Meg Flippin, Benzinga Canoo Inc. (NASDAQ: GOEV), a high-tech advanced mobility company bringing electric vehicles – namely lifestyle delivery vehicles – to commercial operators, seems to have made strides in its quest to create a state-of-the-art EV commercial fleet. The company has inked deals with some of the biggest names in the U.S., including Walmart Inc. (NYSE: WMT), the U.S. Postal Service, the Department of Defense and even NASA. So what makes these large industry players and government agencies want to partner with a relatively unknown brand? After all, Canoo doesn’t have the name recognition of Tesla Inc. (NASDAQ: TSLA). However, it does have scalable technology, which it says sets it apart. EV Is Here to Stay Over the long haul, electric fleets for commercial and government customers have a lower total cost of ownership and don’t require costly fuel. But Canoo says it takes it a step further by using one-third the parts of traditional internal combustion engines (ICEs). The maintenance schedule is almost an afterthought thanks to its advanced computer architecture, which in most cases, can remotely diagnose and repair its EVs via over-the-air (OTA) software. The company also offers a warranty that covers up to eight years, something not common in the auto industry. Canoo is going after the last-mile delivery market with its fully electric Lifestyle Delivery Vehicles (LDV). The LDVs have a last-mile delivery optimized cabin and customized cargo space. Last-mile delivery refers to the very last step of the delivery process when a parcel is moved from one location to another. Canoo reports that it utilizes true steer-by-wire technology, reducing moving parts and cabin intrusion – resulting in more usable interior space, better driver ergonomics and the addition of a panoramic window to improve road visibility. The LDV is engineered for high-frequency stop-and-go deliveries and speedy vehicle-to-door drop-off, including grocery and food/meal delivery, says Canoo. Walmart Is In All those attributes are part of what led Walmart to select Canoo as its EV fleet provider. Walmart inked a deal to purchase 4,500 all-electric delivery vehicles from Canoo, beginning with the LDV. The retailer has the option to purchase up to 10,000 units. The vehicles are to be used to deliver online orders in a sustainable way which will also contribute to Walmart’s goal to achieve zero emissions by 2040, the companies said when originally announcing the deal. Canoo is headquartered in Justin, TX, and operates manufacturing sites in Oklahoma. While that is Canoo’s biggest order to date, the company is also making inroads with the U.S. government, inking deals with NASA, the Department of Defense and the U.S. Postal Service. All have the potential to expand into something more. Take the U.S. Post Office deal for starters. The postal service agreed to buy six right-hand drive versions of the LDV 190 as part of its move to electrify and modernize the postal service’s delivery fleet. Canoo delivered the vehicles this May, and the USPS is using them on mail routes. Additionally, the USPS is investing $40 billion to upgrade and improve the organization's processing, transportation and delivery networks. If it likes what it sees from Canoo, that could mean more purchases down the road. Meanwhile, NASA had also purchased three Crew Transportation Vehicles (CTVs) to transport the astronauts to the launch pad for the Artemis lunar missions. The CTVs are engineered to carry fully suited astronauts, flight support crew and equipment to the launch pad. “We are thrilled to be a part of the Artemis missions and to deliver NASA’s first zero-emission built for mission crew transportation vehicles,” said Tony Aquila, Chairman and CEO of Canoo. “It’s a very proud day for Canoo and all of our partners who worked so hard to ensure we perform our part to transport the astronauts for the first nine miles of every launch.” Beyond LDVs Beyond electric vehicles, Canoo is busy supplying batteries to the Department of Defense, expanding a deal with the U.S. Navy. Canoo’s proprietary battery system is modular and can support various military applications and configurations. The batteries harbor 5kWh modules that utilize 2170 cylindrical cells, but can fit other form factors and cell chemistries. The company says the expansion of the partnership further validates its technology and reliability. It is also delivering the Light Tactical Vehicle (LTV) to the U.S. Army. From fully electric vehicles that can transport cargo, goods and people to batteries powered by wind and solar, Canoo is doing its part for a greener tomorrow. It may not be a household name yet, but with some big-name players as partners, it's one investors may want to keep an eye on. Keep a look out for more Canoo Inc. announcements here. Featured photo courtesy of Canoo. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 09:00 AM Eastern Daylight Time

Image

The New Lithium Environment: How Atlas Lithium Could Be Poised To Capitalize On A Possible 2025 Demand Surge

Benzinga

By Mangeet Kaur Bouns, Benzinga In recent years, lithium has been at the center of the clean energy revolution, driven by its key role in powering electric vehicles (EVs) and other high-demand technologies like energy storage and consumer electronics. Lithium demand surged as many companies have focused on shifting toward greener solutions, leading to soaring prices during the EV boom. However, over the past year, lithium prices have plummeted due to oversupply, with some contracts seeing declines of nearly 90%. While this sharp drop may have concerned many, some market experts predict that lithium demand could strengthen significantly in the coming years, offering a potential window of opportunity for long-term investors to acquire shares in lithium companies at potentially attractive valuations. Companies participating in the supply chain, like Atlas Lithium (NASDAQ: ATLX), could be key players as the market recovers. Lithium’s Sharp Price Decline: A Potential Opportunity? Lithium prices saw an extraordinary boom, particularly between 2021 and 2022, as the global demand for EVs skyrocketed. However, the rapid expansion of lithium production – especially in China – has led to an oversupply situation. As producers ramped up capacity to meet anticipated demand, prices plummeted. Lithium hydroxide, for example, which hit a peak of $85,000 per metric ton in 2022, now trades at approximately $12,000 per metric ton. Similarly, lithium carbonate contracts, which exceeded $40,000 per metric ton just last year, have dropped to around $13,000 per metric ton. This steep decline has shaken confidence in the market, but it could also present a value-buying opportunity. Investors willing to look beyond the short-term oversupply concerns may find the current low prices of some players an appealing entry point. Why Lithium Demand May Rebound In 2025 While supply imbalances have driven down prices, the McKinsey Battery Insights team argues that the demand side of the equation is set for a resurgence, primarily fueled by the accelerating shift toward electric mobility and renewable energy solutions. By 2025 and beyond, the team argues that several key factors could drive a significant increase in lithium demand: Electric vehicle adoption: Some governments are pushing aggressive policies aimed at reducing carbon emissions, and EVs are central to some of these efforts. The U.S. Inflation Reduction Act, the EU’s upcoming ban on internal combustion engine vehicles by 2035 and China’s aggressive EV policies could drive a surge in EV sales. As more automakers transition to electric fleets, demand for lithium-ion batteries, the core component of EVs, could soar. McKinsey predicts that by 2030, up to 90% of passenger vehicle sales in key markets like the U.S., Europe and China could be electric. Energy storage and green energy: Beyond EVs, lithium’s role in renewable energy storage could also play a significant role in future demand. As solar and wind power generation grow, large-scale battery storage solutions will be necessary to store and distribute energy. Lithium-ion batteries are the dominant technology in this space. Technological advancements and policy support: Battery technology improvements could support this demand growth. According to McKinsey's Battery Insights team, global demand for lithium-ion batteries is projected to increase dramatically over the next decade, growing from 700 gigawatt-hours (GWh) in 2022 to an astounding 4.7 terawatt-hours (TWh) by 2030. Long-term demand projections: Data from Statista anticipates that global demand for lithium will surpass 2.4 million metric tons of lithium carbonate equivalent by 2030, doubling from projected 2025 levels. This increase suggests that the current price drop is likely temporary, with supply needing to catch up as demand potentially surges over the next decade. Atlas Lithium: A Potential Play On The Lithium Rebound Amid this shifting landscape, Atlas Lithium could be one company to consider for playing a potential increase in the value of lithium. Based in Brazil, Atlas Lithium says it is advancing its hard-rock lithium project in Minas Gerais, which is among the largest lithium exploration projects in the country. Atlas Lithium argues that its strategic advantage lies not only in its sizable resource base but also in its efficient technological approach to lithium processing. The company is preparing to ship its fabricated modular dense media separation (DMS) lithium processing plant from South Africa to Brazil. This technology is designed to separate lithium-bearing spodumene from other materials, providing a high-grade lithium concentrate crucial for battery production, the company says. Atlas Lithium argues that the DMS plant represents a significant step for Brazil’s lithium industry with a modular design that allows for efficient transportation and installation. Phase 1 of the project aims to produce up to 150,000 tonnes per annum (tpa) of 5.5%-6% battery-grade spodumene. Atlas Lithium’s Position In The Global Supply Chain Atlas Lithium notes that the DMS technology it uses reduces water consumption significantly compared to traditional lithium processing methods, making it an environmentally sustainable way to produce high quality lithium. As ESG (Environmental, Social and Governance) factors become increasingly important to investors, Atlas Lithium argues that its sustainable practices could enhance its appeal. The company believes its recent progress in advancing its Brazilian operations marks a pivotal moment. The upcoming shipment of its processing plant to Brazil, packed into over 100 containers, is a testament to the logistical and operational progress that could allow Atlas to quickly capitalize on a possible new wave of lithium demand, Atlas Lithium asserts. Featured photo by Igor Omilaev on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 08:45 AM Eastern Daylight Time

Image

The Hidden Costs Of Wisdom Teeth Extraction And How One Innovative Company Aims To Eliminate Them

Benzinga

By Mangeet Kaur Bouns, Benzinga Each year, millions of Americans undergo the painful and often expensive process of wisdom teeth removal, a procedure so common that it has become almost a rite of passage for teens and young adults. While many assume this is just an often-necessary part of growing up, the financial and physical toll it takes is staggering. With over 10 million wisdom teeth extracted annually in the U.S., the procedure represents a significant burden on both individuals and the healthcare system. But what if this invasive surgery could be avoided altogether? A new technology developed by TriAgenics aims to do just that, offering a potential future where wisdom teeth never have to be extracted. The Financial And Physical Burden Of Wisdom Teeth Extraction Wisdom teeth removal is the most common surgery performed on teens and young adults, but for many, it can be both financially and physically taxing. The cost of removing a single impacted wisdom tooth averages around $700, with the price for extracting all four often exceeding $3,000. This doesn't even account for the potential complications that can arise – such as dry socket, infection or excessive bleeding – that often extend recovery times and lead to additional expenses. Beyond the direct costs, there's also a significant loss in productivity to consider. On average, patients miss three days of work or school following the procedure, and for some, complications can extend this downtime even further. When multiplied across the millions of patients who undergo this surgery each year, the cumulative impact is substantial. The U.S. spends nearly $5 billion annually on wisdom teeth extraction, a figure that underscores the pervasive nature of this issue. But the economic burden doesn't stop there. Patients over the age of 25 who require wisdom teeth removal face even higher costs, particularly if the teeth are impacted or infected. These cases can be more complex and riskier, often leading to more severe complications and a longer recovery period. This scenario is especially problematic for older adults, who may be more susceptible to complications, thus amplifying both the physical and financial toll. Zero3 TBA: A Potentially Revolutionary Preventative Approach TriAgenics is at the forefront of a potential paradigm shift in dental care with its Zero3 Tooth Bud Ablation (TBA) technology. Unlike traditional wisdom teeth extraction, which involves surgically removing the teeth after they have developed, Zero3 TBA is a preventative procedure designed for children ages 6 to 12. By targeting the tooth buds before they can develop into full-grown wisdom teeth, this innovative approach could eliminate the need for painful extraction entirely. TriAgenics reports that what truly sets Zero3 TBA apart is its minimally invasive nature. Based on extensive animal testing, the procedure takes just 60 to 90 seconds per tooth bud and can be completed in about 30 minutes for four tooth buds, making it significantly less disruptive than traditional extraction. Moreover, it can be performed by general dentists rather than requiring the expertise of an oral surgeon, which not only makes the procedure more accessible but could also reduce costs for patients. The potential implications of this technology are profound. By preventing wisdom teeth from forming, Zero3 TBA could save future generations from the pain, risk and financial burden associated with extraction. It represents a shift from reactive to proactive dental care, focusing on prevention rather than treatment. This approach could fundamentally change how we think about dental health and the management of wisdom teeth. A Comparative Look At Wisdom Teeth Treatment Options When evaluating the different approaches to managing wisdom teeth, TriAgenics' Zero3 TBA may have the potential to offer multiple advantages in terms of cost, risk and outcomes. Zero3 TBA: This procedure, costing approximately $950 per tooth, is the least expensive and least risky option, according to data from TriAgenics. It prevents the formation of wisdom teeth entirely, thereby eliminating the need for future extractions and the associated complications. With no significant recovery time, it promises the best long-term outcomes for patients. Prophylactic Extraction: Typically performed between the ages of 15 and 25, this approach involves removing wisdom teeth before they cause problems. While it aims to prevent more severe issues later in life, the procedure is still relatively costly – around $1,800 per tooth – and carries a moderate risk of post-operative complications. Patients often experience significant pain and a prolonged recovery period. Monitor & Treat: The most expensive and highest-risk option, this method involves regularly monitoring wisdom teeth and treating issues as they arise, which can lead to extraction later in life. With an average cost of $2,800 per tooth, it offers the worst outcomes in terms of both health and financial impact. Older patients are particularly vulnerable to complications. The key takeaway here is that while traditional methods of dealing with wisdom teeth – such as prophylactic extraction or the monitor-and-treat approach – can carry considerable risks and costs, Zero3 TBA seems to stand out as a safer, more cost-effective solution based on the information highlighted above. It has the potential to redefine how wisdom teeth are managed, shifting the focus from reactive surgery to proactive prevention. TriAgenics: The Potential To Transform The Future Of Dental Care TriAgenics could be strategically positioned to revolutionize the dental industry with its Zero3 TBA technology. The company believes this innovation represents the future standard of care for managing wisdom teeth, and its confidence is backed by a 100% success rate in animal trials and a robust intellectual property portfolio that includes 32 U.S. and international patents. With more than $11.5 million in capital raised, TriAgenics is now preparing for FDA 510(k) clearance and human clinical trials, aiming to bring Zero3 TBA to market in 2025. The potential market for Zero3 TBA is vast, with the total addressable market estimated by the company to exceed $2.5 billion annually. This reflects a strong demand for a less invasive, more cost-effective solution to wisdom teeth management. Interest from oral surgeons and pediatric specialists indicates that the healthcare community could be eager for an alternative to traditional extraction, and Zero3 TBA may in that case very well be a game-changer. Click here for more information on TriAgenics and its groundbreaking Zero3 TBA technology. Featured photo by Jéssica Oliveira on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 08:30 AM Eastern Daylight Time

Image

With The Effective End Of The 6% Real Estate Commission Standard, reAlpha’s AI-Powered Homebuying Platform Hopes To Shake Up The Industry

Benzinga

By Meg Flippin, Benzinga The 6% commission standard on real estate deals is expected to be no more, potentially lowering the cost of owning a home. The change is part of a $418 million class-action lawsuit settlement against the National Association of Realtors (NAR), which was accused of inflating the fees paid to real estate agents. Thanks to the settlement, the commission is up for negotiation, which some estimate could result in a 25% to 50% decrease in commission fees that just last year cost Americans $100 billion. This change to the real estate market could also help pave the way for companies providing buyers with tools to streamline the homebuying process, such as reAlpha Tech Corp. (NASDAQ: AIRE). The Dublin, Ohio real estate technology company says it is experiencing strong growth thanks to the launch of its artificial intelligence (AI)-powered, commission-free home buying platform. Buying A Home Can Be Much Easier reAlpha’s AI platform guides users through every stage of the homebuying process and is currently available in 20 Florida counties, with plans for expansion. The platform leverages AI to help customers find homes, make an offer, get a mortgage and close the deal. With reAlpha, users pay zero buy-side commissions, and the company plans to make money by collecting closing costs of 1.2% to 2.47% via mortgage brokering, title and search and home insurance services. reAlpha’s launch comes as the AI market is taking off, forecast to grow to $1.8 trillion by 2030. Advances in machine learning and automation are enabling tech-focused companies to develop AI models that are disrupting many industries. Real estate could also use some innovation, and reAlpha is attempting to capitalize on that, hoping to disrupt the way Robinhood Markets Inc. (NASDAQ: HOOD) did with online investing or Expedia Group Inc. (NASDAQ: EXPE) did for travel. Growing Revenue For Q2 this year, reAlpha reported quarter-over-quarter revenue that rose 205%. The company also closed its buy of Naamche, Inc., a Nepal-based AI technology firm. This acquisition bolstered reAlpha's AI capabilities by adding 42 engineers, developers, analysts and UI/UX designers to its team, increasing the company’s full-time employee count from 15 to 57. reAlpha said the acquisition marks the beginning of the company’s acquisition-led growth strategy, which it said aims to revolutionize the real estate industry through cutting-edge technology. More To Come "We believe that the completion of the Naamche acquisition marked the second quarter of 2024 as the beginning of the ramp-up of our acquisition-led growth strategy," said Giri Devanur, CEO of reAlpha. "We are continuously looking for strategic acquisition opportunities that will advance our mission of bringing innovative technologies to the real estate industry. Naamche's acquisition is one of the early steps in this process." Other acquisitions include AiChat, a Singapore-based company that develops AI-powered conversational customer experience solutions and Hyperfast Title LLC., a title company that’s licensed to operate in Florida, Virginia and Tennessee. With it, reAlpha can offer title services through its platform. Now, reAlpha has added another key piece to its portfolio with the acquisition of Be My Neighbor, a mortgage broker licensed in 26 U.S. states. The company says this acquisition strengthens reAlpha’s AI-powered homebuying platform by incorporating mortgage lending and refinancing services, allowing for a more integrated and seamless customer experience. Be My Neighbor, founded by veterans, will continue to operate under its own brand while leveraging reAlpha's generative AI capabilities. This move is part of reAlpha's broader strategy to vertically integrate the homebuying process, which it says should enhance its commission-free platform and unlock new revenue streams. Looking toward the third quarter, reAlpha is forecasting quarter-over-quarter revenue growth of 140% to 170% in Q3, driven by the integration of its newly acquired companies, AiChat and Hyperfast Title. reAlpha said these acquisitions are expected to enhance its service offerings and contribute significantly to its overall revenue. Taking A Page From Constellation Software reAlpha is only just getting started. The company says it is on the hunt for even more acquisitions as it grows, taking a page from Constellation Software (TSX: CSU ), a Canadian software and services company that has a reputation for acquiring hundreds of software businesses. reAlpha says it hopes to position itself as a trailblazer in the real estate technology sector by strategically acquiring accretive real estate service and technology companies centered around its core platform. “We intend to capitalize on a significant industry shakeup created by the NAR lawsuit. We developed and launched the reAlpha platform after the settlement was announced on March 15, 2024. We are focused on continually improving the product and acquiring additional real estate service companies to unlock more potential sources of revenue,” said Devanur. “We look forward to sharing our growth and developments in the coming quarters, especially after the effects of the NAR settlement take effect on August 17, 2024,” he said. New CFO reAlpha recently announced the appointment of Brent Miller as their new Chief Financial Officer (CFO). Miller, who officially took on the role on Aug. 19, 2024, will be responsible for all financial and accounting operations at reAlpha, reporting directly to the company's president and Chief Operating Officer, Mike Logozzo. Notably, Miller brings valuable experience from his previous role as CFO and treasurer at KKR Real Estate Finance Trust Inc., a commercial mortgage real estate investment trust. During his time there, Miller played a key role in shaping the REIT’s financial strategy, including capital raising and financial reporting. His background with KKR underscores his expertise and makes his appointment at reAlpha a significant development for the company. Featured photo courtesy of reAlpha Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 08:25 AM Eastern Daylight Time

Image

Leading Beauty Retailer Credo Beauty Debuts Private Label Skincare Line: Credo Skincare

Credo Beauty

Credo, the specialty clean beauty retail pioneer, is proud to announce the launch of its own eponymous skincare line, Credo Skincare. The specialty retailer has raised the bar introducing a benefit-driven collection of skincare products focused on the #1 skin concern gathered from clients – hydration – while continuing to challenge and elevate standards for clean and sustainable products and packaging. A cohesive easy to navigate cleanser and moisturizer system meets wanted gold standards. A decade ago, Credo disrupted an underregulated industry as a catalyst for positive change spurring a tidal wave of conscientious product and packaging innovation. Now after accruing 10 years of customer feedback, experience, and data Credo Skincare was developed according to what they found matters most. Ultimately hydration was the stand-out concern for clients. And through in-depth analysis, Credo determined the top ingredient and search terms according to what customers want from their products to deliver that and more. Through their access to the best in business partners, they created results-driven formulas packed with clinically proven actives and sustainably- minded packaging - every aspect of Credo Skincare is transparent and powerfully effective. Credo Skincare’s first collection is comprised of two cleansers ($44 each) and four moisturizers ($64 each) that service skin conditions surrounding primary concerns - dry skin, sensitivity and redness, dullness, and aging - by nourishing the skin and protecting its microbiome through today’s most powerful active combinations. Their formulations are based on key ingredient search terms and skincare concerns. As well, each product contains the transformative power of upcycled vetiver root extract, ethically harvested by a local cooperative in Haiti. Vetiver root is an antioxidant-loaded, potent wonder grass that supports the protection of the skin’s barrier for a vibrant skin tone and a nourished complexion while improving skin texture and reducing the appearance of pores and wrinkles. Credo Skincare’s goals are to provide an easy two step, effective regimen for healthy, hydrated skin that makes customers look and feel their best. Clinicals have proven 27% improvement in hydration after 24 hours, 31% improvement in hydration instantly, and an improvement in the skin barrier function instantly and after 24 hours. ● Deep Thirst Hydrating Cleanser ($44): A transformative formula to deeply cleanse while retaining moisture. ● True Timeout Calming Cleanser ($44): Designed to soothe and calm sensitive skin. ● Deep Thirst Hydrating Moisturizer ($64): Provides intense hydration with lasting effects. ● True Timeout Calming Moisturizer ($64): Helps alleviate sensitivity and redness. ● Radiance Rising Brightening Moisturizer ($64): Brightens dull skin and enhances radiance. ● Rewinder Anti-Aging Moisturizer ($64): Reduces the appearance of wrinkles and fine lines. Beyond that as a retailer, Credo Beauty continues to drive the packaging and social standards that are the hallmarks of tomorrow. Every pump and cap in the Credo Skincare collection is comprised of a first-of-its kind PCR resin, including beauty waste packaging collected in Credo Beauty stores nationwide through Pact Collective, the non-profit Credo Beauty co-founded to divert beauty packaging from landfills. ● The Credo pump was created with Pact’s NewMatter material, a mixture of hard-to-recycle material or landfill and ocean-bound plastic. ● The first run of NewMatter pumps eliminated the need for 500 kg of virgin plastic (500 kg of recycled plastic used is equivalent to 11 cubic meters of landfill space or ~2,900 gallons of space!) ● Every 38 pumps eliminate one pound of material going to the landfill or ocean. “The benefit of listening to 10 years of customers' desires and skin concerns compelled us to create this line. Years of data drove the ingredient compositions of these products so that we could exceed our customers’ expectations for efficacy. Our Credo Clean Standard is already rigorous and difficult to attain but we wanted to challenge ourselves with how our own brand could take clean innovation to new heights from full disclosure of fragrance ingredients and packaging innovation to exceeding the minimum requirements to check certain boxes, Credo Skincare raises the bar on what is possible and what can become the future baseline,” says Co-Founder and CEO Annie Jackson. Availability: Credo Skincare will be available for purchase starting September 12, 2024, at all Credo brick and mortar store locations and on www.credobeauty.com. Media Contact: press@credobeauty.com About Credo Beauty: Credo Beauty offers today’s largest clean and sustainably minded beauty assortment in North America, across color, skincare, haircare and fragrance, partnering with over 120 leading brands, such as Westman Atelier, ILIA, OSEA, True Botanicals and LolaVie. Having built the strictest and lengthy guidelines, “The Credo Clean Standard™”, customers can trust that they are purchasing the most effective, innovative products with safer ingredients with an emphasis on sustainable, natural and ethical materials. Trained makeup artists and estheticians (who are continually being educated by Credo Beauty and our brands) offer an exceptional experience both in-store and online. Visit one of the 15 brick-and-mortar store locations or www.credobeauty.com. Credo Beauty is backed by Next World Evergreen, a San Francisco-based private equity firm that invests in conscious consumer brands across sectors like clean beauty, personal care, health and wellness, sustainable lifestyle, and better-for-you food and beverage. Visit https://www.nextworldevergreen.com/ About Pact Collective: With an industry that generates over 120 billion packages every year, most ending up in landfill – they’re often too small, too flexible, or made of too many materials to be traditionally recycled. All those tiny cosmetic contraptions? They’re headed for the trash. Pact is a nonprofit collective uniting the beauty industry to take responsibility for our packaging waste and work collaboratively toward circular packaging solutions. Visit https://www.pactcollective.org/ Contact Details Amanda Smeal +1 844-692-7336 press@credobeauty.com

September 12, 2024 08:04 AM Eastern Daylight Time

Image

THE WORLD'S PREMIER IMMERSIVE GAMING EXPERIENCE TO UNVEIL ITS FIRST LOCATION IN COLUMBUS THIS SEPTEMBER

Activate

Activate, the trailblazing live-action gaming sensation taking TikTok by storm, will unveil its newest location in Columbus on September 14, 2024, following the success of its first Ohio location in Cincinnati. Guests are invited to dive into the world of immersive gameplay that has captured the hearts of gamers worldwide! This extraordinary venue is set to elevate the entertainment scene to new heights at its vibrant new location: 8735 Lyra Drive, Columbus, OH 43240. From September 14 to 15, Activate is set to launch its grand opening weekend with free admission and extraordinary surprises. Guests can register here. This spectacular new venue will invite an even larger audience to dive into the exhilarating fusion of physical challenges and digital gaming that has made Activate a sensation. Prepare for an unforgettable experience as Activate brings its renowned thrill to a whole new level! Activate is redefining the future of gaming, unleashing its groundbreaking live-action experiences across the U.S. with an unstoppable wave of expansion. With 40 thriving locations worldwide and a staggering 2.5 million players, Activate combines state-of-the-art technology with heart-pounding challenges, creating an adrenaline-fueled social adventure like no other. This isn't just gaming; it's an electrifying global phenomenon that’s captivating players worldwide. "We're beyond excited to bring Activate to Columbus and share our passion for cutting-edge, interactive adventures," says Will Gray, Director of Marketing at Activate. "This new location will offer our signature mix of physical excitement and digital fun to even more people. We can't wait to light up this vibrant community with the thrill of our unique gaming experience and welcome a whole new group of adventurers." Activate Columbus's cutting-edge gaming facility invites players of all ages and skill levels to explore and create their unique gaming experiences. Here’s what to expect: Top gaming rooms include the TikTok viral sensation Mega Grid with 500+ multi-activated rainbow-colored tiles, blasting the beaming bullseye in a game called Strike, and feel like a modern-day spy in the Laser room. Guests can sign up in groups of two to five players. Through progress tracking via Activate’s high-tech electronic RFID wristbands, players can rack up points, leveling up and earning prizes along the way. Try Level 1 easy or take it to Level 10 extreme. Play as a team in cooperative mode, or challenge your friends in competitive mode games. Additional Activate locations are set to open in 2024 across the U.S. in markets such as Detroit, Bloomington and Austin. Today, Activate operates over 40 locations across Canada and the U.S. PLAN YOUR VISIT Wear activewear and flat, closed-toe shoes. Where: 8735 Lyra Drive Columbus, OH 43240. When: Monday through Thursday, 12 p.m to 9 p.m. | Friday, 10 a.m to 11 p.m | Saturday, 9 a.m. to 11 p.m. | Sunday, 9 a.m. to 10 p.m. Cost: Starting at $19.99 per player Mon-Thurs and $24.99 per player Fri-Sun (and Holidays). For a sneak peek into Activate’s action-packed gaming experience, click here. Click here for high-res assets Activate is the world’s first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 30 locations across Canada, the U.S. and now the world! To join the active gaming movement, visit playactivate.com. Follow Activate on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames Contact Details Jive PR + Digital Jalila Singerff +1 613-614-6777 jalila@jiveprdigital.com Company Website https://playactivate.com

September 12, 2024 08:00 AM Eastern Daylight Time

Milemarker Unveils Firm Intelligence: The Power to Control, Integrate, and Unlock Your Wealth Management Data

Milemarker

Milemarker, a fintech firm dedicated to empowering wealth management companies with deeper insights from their existing tech stacks, today announced the launch of its groundbreaking platform, Firm Intelligence. This innovative solution is set to revolutionize how financial advisors automate processes, integrate systems, and communicate with clients and prospects. Founded in 2021, Milemarker has swiftly become the go-to platform for financial advisors seeking to extract more value from their disparate technology providers. By synthesizing data across various systems, Milemarker delivers a streamlined, operational, and client-service-level solution that enhances efficiency and drives growth. “Milemarker is the connective tissue that allows firms to harness data insights to better manage their clients and scale their businesses,” said Milemarker CEO Kyle Van Pelt. “With the launch of Firm Intelligence, we’re enabling wealth management firms to maximize the potential of their current tech stacks, allowing them to focus their time and resources on what truly matters: serving clients and engaging with prospects.” Milemarker serves advisory firms managing assets ranging from $250 million to over $200 billion. For these firms, mergers and acquisitions are often strategic priorities, yet they present significant challenges when onboarding businesses with different technology systems. Milemarker addresses this integration gap by automating workflows and creating broader data connectivity through one seamless, easy-to-use platform. “Given the rapid pace of technological advancement, expecting wealth management firms to invest in new tools continuously is neither practical nor cost-effective,” said Milemarker Co-Founder and Managing Partner Jud Mackrill. “With Milemarker, we’re advocating for a smarter approach: invest in your people and processes, and let us help you get the most out of the technology you already have. We empower financial advisors to enhance their use of technology while delivering a clear return on investment.” Milemarker’s Firm Intelligence consolidates all essential data into a single pane of glass. Financial advisory firms can seamlessly integrate Milemarker into their systems or engage with it through a branded application that can live on their domain and be entirely privately labeled to their brand. In just two years, Milemarker has built a fast-growing company with team members across the United States and an impressive roster of some of today’s fastest-growing advisory firms. “Thanks to Milemarker Firm Intelligence, our leadership team and advisors now have greater access to the data we need to effectively run our business,” said SignatureFD Chief Information Officer Laura Hubbell. “We’ve been able to automatically create reports that would have otherwise taken us weeks– including some that would have been nearly impossible to do. We’re in a new era of transparency and automation of data in our business.” Following the platform’s launch, Milemarker is set to roll out several new features and enhancements in the coming months, further solidifying its position as a leader in fintech innovation for wealth management. About Milemarker Milemarker is the force behind the next evolution in wealth management technology. Founded in 2022, we empower advisory firms to break free from fragmented data and disjointed systems. Our platform, Firm Intelligence, is where data meets clarity—synthesizing insights, automating workflows, and putting advisors back in the driver’s seat of their tech stack. We don’t just integrate systems; we amplify their value. With Milemarker, your technology finally works for you, not the other way around. Because in a world where every second counts, your focus should be on what truly matters—growing your firm and serving your clients. Own your data. Amplify your impact. Contact Details For Milemarker Jud Mackrill +1 402-651-7679 jud@milemarker.co Company Website https://milemarker.co/

September 12, 2024 08:00 AM Eastern Daylight Time

News Release

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

OSTX ATNM PBYI CRBP

In oncology, the relentless drive for innovation is forging new paths in cancer treatment. The field is rapidly evolving with advances in targeted therapies, immunotherapies, and novel technologies, each promising to reshape patient outcomes. Let’s explore some standout stocks that are leading the charge in this transformative era of cancer care with their cutting-edge approaches and pioneering therapies. OS Therapies Inc. (NYSEAmerican: OSTX) is gaining attention in the biotech space for its cutting-edge approaches to treating osteosarcoma and other solid tumors through immunotherapy and antibody drug conjugate (ADC) platforms. The company’s focus on developing next-generation therapeutics and its recent positive data make it a compelling candidate for investors seeking exposure to innovative cancer treatments. Advancing Immunotherapy with OST-HER2 The company's lead asset, OST-HER2, is a novel immunotherapy designed to treat resected, recurrent osteosarcoma. This treatment utilizes Listeria bacteria to stimulate the immune system to target the HER2 protein. OS Therapies has recently completed enrollment for its Phase 2b clinical trial involving 41 patients, with results expected in the fourth quarter of 2024. OST-HER2 aims to prevent metastasis, delay recurrence, and increase overall survival, representing a potential breakthrough for a disease that has not seen significant advancements in decades. If successful, this treatment could address the unmet need for effective adjuvant therapies in osteosarcoma, offering hope to patients with recurrent disease. Innovative Antibody Drug Conjugate Platform OS Therapies is also making strides with its tunable ADC (tADC) platform, leveraging its proprietary SiLinker technology. The platform incorporates pH-sensitive silicon-based linkers capable of releasing multiple therapeutic agents selectively within the tumor microenvironment. Recent preclinical data on their ovarian cancer therapeutic candidate, OST-tADC-FRA-H, showcased strong antitumor activity in mouse models and a favorable safety profile with no significant loss of body weight among treated animals. This preclinical success demonstrates the potential of OS Therapies' technology to enhance the efficacy and safety of ADCs, paving the way for multiple new therapeutic candidates. The company's SiLinker technology is not just about delivering payloads; it also holds the promise of improving existing ADC combinations or creating entirely new intellectual properties. This flexibility could position OS Therapies as a key player in the growing ADC market, which is projected to reach $20.9 billion by 2030, according to Grandview Research. Strategic Collaborations and Industry Recognition OS Therapies' potential is further underscored by its acceptance into Johnson & Johnson Innovation (JLABS), which provides access to resources that could accelerate the development of its tADC platform. This membership could facilitate critical partnerships and collaborations, enhancing the company’s ability to bring its innovative therapies to market. Additionally, OS Therapies has formed both a Patient Advocacy Advisory Board (PAAB) and a Scientific and Medical Advisory Board (SMAB), drawing expertise from leading institutions such as Texas Children’s Hospital, the Cleveland Clinic, and the University of California, San Francisco. These boards will guide the company as it engages with the FDA and prepares for a potential Biologics License Authorization (BLA) for OST-HER2. This strategic alignment with top medical professionals and patient advocates strengthens OS Therapies’ position in navigating the regulatory landscape and underscores its commitment to addressing patient needs. Promising Market Opportunity With its innovative pipeline, strategic collaborations, and strong leadership, OS Therapies is well-positioned to capitalize on the expanding oncology market. The ongoing development of OST-HER2 and the tADC platform could lead to significant milestones, including potential FDA approvals that would not only validate its scientific approach but also create substantial market opportunities. As a clinical-stage company with promising technologies and strategic industry support, OS Therapies represents a compelling investment opportunity in the biopharmaceutical sector. Actinium Pharmaceuticals, Inc. (NYSEAmerican: ATNM) is developing targeted radiotherapies to improve treatment outcomes for patients with blood cancers and other serious conditions. Their lead candidate, Iomab-B, is in late-stage development as a conditioning agent for bone marrow transplants, with potential U.S. and European regulatory submissions on the horizon. Actimab-A, another promising candidate, is targeting relapsed and refractory acute myeloid leukemia (AML) and is developed in partnership with the National Cancer Institute. The company recently advanced Iomab-ACT, designed for conditioning before bone marrow transplants in sickle cell disease patients, with the potential to offer a safer, non-chemotherapy alternative. This targeted approach aims to minimize the toxicities typically seen with traditional conditioning methods, positioning Iomab-ACT as a unique option in a growing market driven by expanding cell and gene therapy applications. Actinium’s strategy is bolstered by a strong intellectual property portfolio with over 230 patents, including new protections for Iomab-ACT in gene therapy conditioning for non-malignant conditions. However, the company faces a regulatory hurdle as the FDA has requested an additional clinical trial for Iomab-B after a mixed outcome in its Phase 3 trial. Actinium is now seeking a partner to help advance Iomab-B while focusing on its broader pipeline. With a unique technology platform and a growing addressable market in cell and gene therapies, Actinium Pharmaceuticals holds potential as an emerging player in the targeted radiotherapy space. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is positioning itself as a key player in precision oncology, with promising advancements in its clinical pipeline. The company's leading asset, CRB-701, a next-generation antibody-drug conjugate (ADC), targets Nectin-4, a well-validated cancer marker. Recent clinical data from the ASCO 2024 conference show encouraging results in both metastatic urothelial cancer and cervical cancer. CRB-701 delivered an overall response rate (ORR) of 44% in mUC and 43% in cervical cancer, with strong disease control rates (DCR) of 78% and 86%, respectively. Importantly, no major toxicities have been observed at higher doses, positioning CRB-701 as a potentially safer option in its class. Corbus expects to complete the Phase 1 dose escalation study for CRB-701 by Q4 2024, with data presentation planned for early 2025. This upcoming milestone could serve as a major catalyst for the stock, particularly if the safety and efficacy data continue to align with the results seen so far. Additionally, Corbus is advancing its other assets, including CRB-601, which targets the tumor microenvironment, and CRB-913, a treatment for obesity. Both programs are expected to enter clinical trials by early 2025, broadening the company’s pipeline and increasing its potential value. Financially, Corbus is in a strong position, with $147 million in cash and investments as of June 30, 2024. This provides the company with a cash runway through Q3 2027, allowing it to advance its key programs without the immediate need for additional capital raises. Recent fundraising efforts, including $35.6 million raised through its ATM program, further strengthen the company's financial foundation. For investors, Corbus represents a high-potential opportunity, particularly with multiple clinical milestones on the horizon. The company’s focus on innovative, targeted therapies in oncology, combined with its solid financial standing, makes it a stock to watch in the biotech sector. Puma Biotechnology, Inc. (NASDAQ: PBYI) is a biopharmaceutical company focused on developing and commercializing treatments to enhance cancer care. Puma licensed the global rights to PB272 in 2011, and in 2017, the U.S. FDA approved neratinib for extended adjuvant treatment of early-stage HER2-positive breast cancer following trastuzumab-based therapy. Marketed under the name NERLYNX in the U.S., the drug received further FDA approval in 2020 for combination use with capecitabine to treat advanced or metastatic HER2-positive breast cancer after two or more prior anti-HER2-based regimens. NERLYNX also gained marketing authorization in the EU in 2018 for the extended adjuvant treatment of hormone receptor-positive, HER2-overexpressed breast cancer patients within a year of completing trastuzumab therapy. In September 2022, Puma entered into an exclusive license agreement for alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, initially targeting small-cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA-Lung1, a Phase II trial of alisertib monotherapy for extensive stage small cell lung cancer. In June 2024, data on alisertib's use in advanced osimertinib-resistant EGFR-mutated non-small cell lung cancer was presented at the ASCO Annual Meeting. The Phase I/Ib study evaluated 21 patients who progressed on osimertinib monotherapy, with alisertib doses of 30 mg and 40 mg twice daily in combination with osimertinib 80 mg daily. The 30 mg dose was identified as the maximum tolerated dose and recommended Phase II dose. The study reported an overall response rate of 9.5% and a disease control rate of 81%. Median progression-free survival (PFS) was 5.5 months, with median overall survival (OS) of 23.5 months. Subgroup analysis showed differences in outcomes based on TP53 mutation status, with patients who were TP53 wild-type experiencing a higher overall response rate and longer PFS compared to those with TP53 mutations. Based on these findings, Puma is modifying the trial protocol to focus on the TP53 wild-type cohort. For the second quarter of 2024, Puma reported revenue of $47.1 million, down 14% from the previous year but still exceeding analyst estimates by 5.4%. Earnings per share also beat estimates by 9.1%. Despite these beats, the company posted a net loss of $4.53 million, a significant drop from a $2.13 million profit in the same quarter last year. Looking ahead, Puma’s revenue is projected to decline by 2% annually over the next three years, contrasting with the 18% growth expected in the U.S. biotech sector. Additionally, on August 5, 2024, Puma granted a restricted stock unit award covering 3,500 shares to a new non-executive employee under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years and serves as an inducement for employment in line with Nasdaq rules. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OS Therapies Inc. to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

September 12, 2024 07:59 AM Eastern Daylight Time

All Industries

TEAM 1144's New Initiative lead by Nesty Delgado: Launch of the Project Management & Transformational Leadership Institute

This EV-Based Small Cap Has Partnerships With Walmart, NASA And The U.S. Postal Service – Is It On Your Radar?

The New Lithium Environment: How Atlas Lithium Could Be Poised To Capitalize On A Possible 2025 Demand Surge

The Hidden Costs Of Wisdom Teeth Extraction And How One Innovative Company Aims To Eliminate Them

With The Effective End Of The 6% Real Estate Commission Standard, reAlpha’s AI-Powered Homebuying Platform Hopes To Shake Up The Industry

Leading Beauty Retailer Credo Beauty Debuts Private Label Skincare Line: Credo Skincare

THE WORLD'S PREMIER IMMERSIVE GAMING EXPERIENCE TO UNVEIL ITS FIRST LOCATION IN COLUMBUS THIS SEPTEMBER

Milemarker Unveils Firm Intelligence: The Power to Control, Integrate, and Unlock Your Wealth Management Data

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector